Novel Treatment Options for Portal Hypertension

Overview

Journal Gastroenterol Rep (Oxf)

Specialty Gastroenterology

Date 2017 May 24

PMID 28533907

Citations 16

Authors

Philipp Schwabl

Wim Laleman

Affiliations

Soon will be listed here.

Abstract

Portal hypertension is most frequently associated with cirrhosis and is a major driver for associated complications, such as variceal bleeding, ascites or hepatic encephalopathy. As such, clinically significant portal hypertension forms the prelude to decompensation and impacts significantly on the prognosis of patients with liver cirrhosis. At present, non-selective β-blockers, vasopressin analogues and somatostatin analogues are the mainstay of treatment but these strategies are far from satisfactory and only target splanchnic hyperemia. In contrast, safe and reliable strategies to reduce the increased intrahepatic resistance in cirrhotic patients still represent a pending issue. In recent years, several preclinical and clinical trials have focused on this latter component and other therapeutic avenues. In this review, we highlight novel data in this context and address potentially interesting therapeutic options for the future.

Citing Articles

Recent Approaches in Portal Hypertension Involving Risk Stratification and Medical Management.

Patel M, Hunt C, VanWagner L Gastroenterol Hepatol (N Y). 2024; 19(11):662-669.

PMID: 38405225 PMC: 10882863.

The rationale and study design of two phase II trials examining the effects of BI 685,509, a soluble guanylyl cyclase activator, on clinically significant portal hypertension in patients with compensated cirrhosis.

Reiberger T, Berzigotti A, Trebicka J, Ertle J, Gashaw I, Swallow R Trials. 2023; 24(1):293.

PMID: 37095557 PMC: 10123479. DOI: 10.1186/s13063-023-07291-3.

Ha Y, Jeong I, Kim T Biomedicines. 2022; 10(10).

PMID: 36289791 PMC: 9599689. DOI: 10.3390/biomedicines10102530.

Downregulation of Ca-Activated Cl Channel TMEM16A Mediated by Angiotensin II in Cirrhotic Portal Hypertensive Mice.

Kondo R, Furukawa N, Deguchi A, Kawata N, Suzuki Y, Imaizumi Y Front Pharmacol. 2022; 13:831311.

PMID: 35370660 PMC: 8966666. DOI: 10.3389/fphar.2022.831311.

The Hepatic Sinusoid in Chronic Liver Disease: The Optimal Milieu for Cancer.

Gibert-Ramos A, Sanfeliu-Redondo D, Aristu-Zabalza P, Martinez-Alcocer A, Gracia-Sancho J, Guixe-Muntet S Cancers (Basel). 2021; 13(22).

PMID: 34830874 PMC: 8616349. DOI: 10.3390/cancers13225719.

References

Vlachogiannakos J, Viazis N, Vasianopoulou P, Vafiadis I, Karamanolis D, Ladas S . Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. J Gastroenterol Hepatol. 2012; 28(3):450-5. DOI: 10.1111/jgh.12070. View

Gracia-Sancho J, Lavina B, Rodriguez-Vilarrupla A, Brandes R, Fernandez M, Bosch J . Evidence against a role for NADPH oxidase modulating hepatic vascular tone in cirrhosis. Gastroenterology. 2007; 133(3):959-66. DOI: 10.1053/j.gastro.2007.06.021. View

Hsu S, Lee F, Wang S, Hsin I, Lin T, Huang H . Caffeine ameliorates hemodynamic derangements and portosystemic collaterals in cirrhotic rats. Hepatology. 2015; 61(5):1672-84. DOI: 10.1002/hep.27679. View

Pockros P, Schiff E, Shiffman M, McHutchison J, Gish R, Afdhal N . Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. Hepatology. 2007; 46(2):324-9. DOI: 10.1002/hep.21664. View

Uschner F, Ranabhat G, Choi S, Granzow M, Klein S, Schierwagen R . Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension. Sci Rep. 2015; 5:14573. PMC: 4585958. DOI: 10.1038/srep14573. View

Herath C, Warner F, Lubel J, Dean R, Jia Z, Lew R . Upregulation of hepatic angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1-7) levels in experimental biliary fibrosis. J Hepatol. 2007; 47(3):387-95. PMC: 7114685. DOI: 10.1016/j.jhep.2007.03.008. View

Halilbasic E, Fuchs C, Traussnigg S, Trauner M . Farnesoid X Receptor Agonists and Other Bile Acid Signaling Strategies for Treatment of Liver Disease. Dig Dis. 2016; 34(5):580-8. DOI: 10.1159/000445268. View

Austin A, Mahida Y, Clarke D, Ryder S, Freeman J . A pilot study to investigate the use of oxpentifylline (pentoxifylline) and thalidomide in portal hypertension secondary to alcoholic cirrhosis. Aliment Pharmacol Ther. 2003; 19(1):79-88. DOI: 10.1046/j.1365-2036.2003.01809.x. View

Klein S, Herath C, Schierwagen R, Grace J, Haltenhof T, Uschner F . Hemodynamic Effects of the Non-Peptidic Angiotensin-(1-7) Agonist AVE0991 in Liver Cirrhosis. PLoS One. 2015; 10(9):e0138732. PMC: 4583473. DOI: 10.1371/journal.pone.0138732. View

10.

Debernardi-Venon W, Martini S, Biasi F, Vizio B, Termine A, Poli G . AT1 receptor antagonist Candesartan in selected cirrhotic patients: effect on portal pressure and liver fibrosis markers. J Hepatol. 2007; 46(6):1026-33. DOI: 10.1016/j.jhep.2007.01.017. View

11.

Colle I, De Vriese A, Van Vlierberghe H, Lameire N, Devos M . Systemic and splanchnic haemodynamic effects of sildenafil in an in vivo animal model of cirrhosis support for a risk in cirrhotic patients. Liver Int. 2004; 24(1):63-8. DOI: 10.1111/j.1478-3231.2004.00892.x. View

12.

Clemmesen J, Giraldi A, Ott P, Dalhoff K, Hansen B, Larsen F . Sildenafil does not influence hepatic venous pressure gradient in patients with cirrhosis. World J Gastroenterol. 2008; 14(40):6208-12. PMC: 2761583. DOI: 10.3748/wjg.14.6208. View

13.

Watanabe N, Takashimizu S, Nishizaki Y, Kojima S, Kagawa T, Matsuzaki S . An endothelin A receptor antagonist induces dilatation of sinusoidal endothelial fenestrae: implications for endothelin-1 in hepatic microcirculation. J Gastroenterol. 2007; 42(9):775-82. DOI: 10.1007/s00535-007-2093-1. View

14.

Rosado E, Rodriguez-Vilarrupla A, Gracia-Sancho J, Monclus M, Bosch J, Garcia-Pagan J . Interaction between NO and COX pathways modulating hepatic endothelial cells from control and cirrhotic rats. J Cell Mol Med. 2012; 16(10):2461-70. PMC: 3823440. DOI: 10.1111/j.1582-4934.2012.01563.x. View

15.

Fiorucci S, Antonelli E, Brancaleone V, Sanpaolo L, Orlandi S, Distrutti E . NCX-1000, a nitric oxide-releasing derivative of ursodeoxycholic acid, ameliorates portal hypertension and lowers norepinephrine-induced intrahepatic resistance in the isolated and perfused rat liver. J Hepatol. 2003; 39(6):932-9. DOI: 10.1016/s0168-8278(03)00393-3. View

16.

Zhang L, Wang Y, Chen W, Wang X, Lou G, Liu N . Promotion of liver regeneration/repair by farnesoid X receptor in both liver and intestine in mice. Hepatology. 2012; 56(6):2336-43. PMC: 3477501. DOI: 10.1002/hep.25905. View

17.

Inagaki T, Moschetta A, Lee Y, Peng L, Zhao G, Downes M . Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A. 2006; 103(10):3920-5. PMC: 1450165. DOI: 10.1073/pnas.0509592103. View

18.

Marrone G, Maeso-Diaz R, Garcia-Cardena G, Abraldes J, Garcia-Pagan J, Bosch J . KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins. Gut. 2014; 64(9):1434-43. DOI: 10.1136/gutjnl-2014-308338. View

19.

Laleman W, Landeghem L, Wilmer A, Fevery J, Nevens F . Portal hypertension: from pathophysiology to clinical practice. Liver Int. 2005; 25(6):1079-90. DOI: 10.1111/j.1478-3231.2005.01163.x. View

20.

Lopez-Talavera J, Cadelina G, Olchowski J, Merrill W, Groszmann R . Thalidomide inhibits tumor necrosis factor alpha, decreases nitric oxide synthesis, and ameliorates the hyperdynamic circulatory syndrome in portal-hypertensive rats. Hepatology. 1996; 23(6):1616-21. DOI: 10.1002/hep.510230644. View